Benjamin Lopez

Benjamin Lopez

Auto-generated profile, based on publicly available information

Benjamin Lopez

CHU Lille, Institut d'Immunologie

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Laboratory Investigation
Verified
Journal Article
Closed access
JGJean-Baptiste Gibier
Jean-Baptiste Gibier
VGViviane Gnemmi
Viviane Gnemmi
FGFrançois Glowacki
François Glowacki
EBEileen M Boyle
Eileen M Boyle
BLBenjamin Lopez
Benjamin Lopez
DBDavid Buob
David Buob

20 December 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
BLBenjamin Lopez
Benjamin Lopez
MBMathilde Bahuaud
Mathilde Bahuaud
CFClaire Fieschi
Claire Fieschi
SMSouad Mehlal
Souad Mehlal
MJMohamed Jeljeli
Mohamed Jeljeli
GLGuillaume Lefèvre
Guillaume Lefèvre
Background: An overall response assay [OVA, based on a 23-valent pneumococcal polysaccharide vaccine (PPV23)] is widely used to screen for anti-pneumococcal antibodies. Given the heterogeneity of response from one polysaccharide (PS) to another, a World Health Organization-standardized serotype-specific enzyme-linked immunosorbent assay (SSA) is considered to be the only reliable method for testing anti-PS antibody responses in individuals with suspected primary immunodeficiencies (PIDs). Objective: To evaluate the OVA relative to the reference SSA. Methods: Serum samples of adult patients referred for a suspected PID were collected before and then 4–8 weeks after immunization with PPV23. The anti-pneumococcal response was systematically assessed with an SSA (7–16 serotypes) and interpreted according to the American Academy of Asthma, Allergy and Immunology’s current guidelines. We used receiver operating characteristic curves and agreement indices to assess the OVA’s diagnostic value in a first cohort. In order to validate these findings, a second (validation) cohort was then prospectively included. Results: Sixty-two adult patients were included, and 42 (67.7%) were defined as poor responders according to the SSA. Only the post-immunization titer in the OVA was able to correctly identify poor responders; a titer below 110 mg/L gave a positive predictive value of 100% [identifying 24 (57.1%) of the 42 poor responders], and similar levels of diagnostic performance were observed in the validation cohort. The pre-vaccination antibody titer, the post/pre-vaccination antibody titer ratio and a post-vaccination titer above 110 mg/L in the OVA were not predictive of the response in the SSA. Conclusion: A post-vaccination antibody titer below 110 mg/L in the OVA was constantly associated with a poor PPV23 response using the SSA. In all other cases, SSA is the only reliable method for assessing diagnostic vaccination with PPV23.

1 August 2017 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
SSSEBASTIEN SANGES
SEBASTIEN SANGES
FWF. Wallet
F. Wallet
NBN. Blondiaux
N. Blondiaux
DTD. Theis
D. Theis
IVI. Vérin
I. Vérin
GLG. Lefèvre
G. Lefèvre

1 September 2021 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
PDPaul Decker
Paul Decker
TMThomas Moulinet
Thomas Moulinet
BLBenjamin Lopez
Benjamin Lopez
SDSylvain Dubucquoi
Sylvain Dubucquoi
BBBernard Bonnotte
Bernard Bonnotte
RJRoland Jaussaud
Roland Jaussaud

13 April 2017 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
JBJocelyn Bellier
Jocelyn Bellier
JPJean Yannis Perentes
Jean Yannis Perentes
EAEtienne Abdelnour-Berchtold
Etienne Abdelnour-Berchtold
BLBenjamin Lopez
Benjamin Lopez
TKThorsten Krueger
Thorsten Krueger
MGMichel Gonzalez
Michel Gonzalez

1 December 2016 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
HWHélène Wattez
Hélène Wattez
TMTeresa Martin-Gonzalez
Teresa Martin-Gonzalez
BLBenjamin Lopez
Benjamin Lopez
RSRafaëlle Spear
Rafaëlle Spear
RCRachel E. Clough
Rachel E. Clough
SHStéphan Haulon
Stéphan Haulon